Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Lilly and Incyte report positive study data for rheumatoid arthritis drug

Lilly and Incyte report positive study data for rheumatoid arthritis drug

9th November 2016

Lilly and Incyte have announced new clinical data showing the benefits their drug baricitinib can provide for rheumatoid arthritis patients.

Results from the phase III RA-BEACON study showed baricitinib delivered significant improvements in patient-reported outcomes, health-related quality of life measures, fatigue and pain among patients with moderate to severe rheumatoid arthritis.

The study compared the performance of Lilly and Incyte's drug to placebo among patients who had experienced an insufficient response or intolerance to previous treatment with biologic disease-modifying antirheumatic drugs, including tumor necrosis factor inhibitors.

Treatment with baricitinib over 24 weeks significantly improved most patient-reported outcomes compared with placebo, with those receiving a four mg dose showing the most rapid and greatest change.

Dr Terence Rooney, Lilly's senior medical director for baricitinib, said: "If approved, baricitinib may help address some of the challenges patients with rheumatoid arthritis who are not achieving remission or low disease activity with their current biologic therapy face when performing daily activities."

Baricitinib is currently being assessed for potential approval as a rheumatoid arthritis therapy by regulators in the US, Europe and Japan.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801828108-ADNFCR

We have hundreds of jobs available across the Healthcare industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.